Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|August 8, 2018

Global Risk Based Monitoring: An Invite from Oxford and Duke Research

CBI, the conference group sister of Applied Clinical Trials, is featuring their Global Risk Based Monitoring Conference in September.

CBI, the conference group sister of Applied Clinical Trials, is featuring their [cbinet.com/globalrbm] Global Risk Based Monitoring Conference in September. CBI Conference Producer, Trevor Sosvielle, recently worked with Lisa Berdan, Director of Global Mega Trials at Duke Clinical Research Institute and Carol Knott, Head of Monitoring and Nurse Training at the University of Oxford to discuss their participation and insight into this event.

 

A letter to our colleagues:

  We are pleased to invite you to join us at CBI’s Global Risk-Based Monitoring being held 13-14 September, 2018 in London UK at the

Amba Hotel Marble Arch

. We’ve created an 

agenda

 that blends roundtable discussions along with key presentations to maximize interactive discussions.   Whether you are developing your first RBM strategy or fully immersed in global RBM implementation, we’ve included topics that align with all stages of RBM implementation:

  • Create efficiencies for your central monitoring team

  • Evaluate RBM capabilities of your CROs/AROs

  • Benchmark against global industry leaders from around the world

  • Determine the right trial to implement RBM

  • Create a library of RACTS and risk classifications

  • Adapt your RBM strategy to ICH E6 (R2) 

We’ve selected key industry and academic research experts to share their experiences and perspectives on RBM and its implementation. We are eager to have you join us in London this September to share your own RBM experiences and expand this global professional network with us in an interactive setting.   We look forward to seeing you in London!   Best Regards, Lisa Berdan and Carol Knott


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.